Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$20.04 -2.9%	$19.22	$15.47 ▼ $36.37	$685.63M	1.47	184,018 shs	302,038 shs
CRNX Crinetics Pharmaceuticals	$29.91 +1.4%	$31.00	$24.10 ▼ $62.53	$2.80B	0.31	855,373 shs	900,068 shs
IMVT Immunovant	$14.10 -1.3%	$15.15	$12.72 ▼ $34.47	$2.40B	0.75	1.23 million shs	1.43 million shs
MLTX MoonLake Immunotherapeutics	$38.17 -1.1%	$38.33	$31.42 ▼ $58.26	$2.44B	1.31	352,448 shs	221,888 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-2.86%	-2.10%	-4.21%	-15.44%	+5.64%
CRNX Crinetics Pharmaceuticals	+1.39%	-0.13%	-9.66%	-9.94%	-36.17%
IMVT Immunovant	-1.33%	-2.15%	-8.56%	-30.37%	-50.39%
MLTX MoonLake Immunotherapeutics	-1.06%	-0.96%	-2.50%	-8.62%	-8.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
AVBP ArriVent BioPharma	1.1622 of 5 stars	3.6	0.0	0.0	2.8	0.0
CRNX Crinetics Pharmaceuticals	3.8308 of 5 stars	3.5	1.0	3.7	4.1	2.5
IMVT Immunovant	2.2401 of 5 stars	4.5	0.0	0.0	2.9	1.7
MLTX MoonLake Immunotherapeutics	2.9724 of 5 stars	4.5	1.0	0.0	3.6	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	96.04% Upside
CRNX Crinetics Pharmaceuticals	2.91	Moderate Buy	$74.56	149.27% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	171.87% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$78.71	106.22% Upside

Current Analyst Ratings Breakdown

Latest AVBP, CRNX, MLTX, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/19/2025	MLTX MoonLake Immunotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$61.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$78.00 ➝ $80.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/30/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00
3/25/2025	CRNX Crinetics Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
3/20/2025	AVBP ArriVent BioPharma	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
3/20/2025	IMVT Immunovant	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/20/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
CRNX Crinetics Pharmaceuticals	$760K	3,684.79	N/A	N/A	$8.07 per share	3.71
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.08 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$8.15 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$214.53M	-$3.82	N/A	N/A	N/A	N/A	-36.12%	-31.89%	8/6/2025 (Estimated)
IMVT Immunovant	-$259.34M	-$2.62	N/A	N/A	N/A	N/A	-77.94%	-69.82%	6/4/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$36.01M	-$2.30	N/A	N/A	N/A	N/A	-15.54%	-15.09%	8/6/2025 (Estimated)

Latest AVBP, CRNX, MLTX, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/4/2025	Q4 2025	IMVT Immunovant	-$0.72	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
3/3/2025	Q4 2024	AVBP ArriVent BioPharma	-$0.78	-$0.60	+$0.18	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
CRNX Crinetics Pharmaceuticals	N/A	16.39	16.38
IMVT Immunovant	N/A	6.04	6.04
MLTX MoonLake Immunotherapeutics	N/A	25.51	25.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
CRNX Crinetics Pharmaceuticals	98.51%
IMVT Immunovant	47.08%
MLTX MoonLake Immunotherapeutics	93.85%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	N/A
CRNX Crinetics Pharmaceuticals	4.60%
IMVT Immunovant	5.90%
MLTX MoonLake Immunotherapeutics	12.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
CRNX Crinetics Pharmaceuticals	210	93.63 million	87.17 million	Optionable
IMVT Immunovant	120	169.86 million	159.84 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.22 million	Optionable

AVBP, CRNX, MLTX, and IMVT Headlines

Recent News About These Companies

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

May 27 at 4:12 PM | insidermonkey.com

BNP Paribas Financial Markets Takes $413,000 Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 27 at 3:13 AM | marketbeat.com

Woodline Partners LP Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 24, 2025 | marketbeat.com

Nuveen Asset Management LLC Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 24, 2025 | marketbeat.com

Point72 Asset Management L.P. Invests $5.35 Million in MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 22, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Wolfe Research to Outperform Rating

May 21, 2025 | marketbeat.com

Wexford Capital LP Purchases 10,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 21, 2025 | marketbeat.com

Ameriprise Financial Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 21, 2025 | marketbeat.com

Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX)

May 20, 2025 | msn.com

Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform"

May 20, 2025 | americanbankingnews.com

Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) with a Bullish Outlook | MLTX Stock News

May 19, 2025 | gurufocus.com

Ensign Peak Advisors Inc Sells 33,174 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 19, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from Analysts

May 19, 2025 | marketbeat.com

Polar Capital Holdings Plc Raises Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 17, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by MPM Bioimpact LLC

May 16, 2025 | marketbeat.com

Paradigm Biocapital Advisors LP Purchases 840,731 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 16, 2025 | marketbeat.com

Parkman Healthcare Partners LLC Has $2.94 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 16, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Lowered by Schonfeld Strategic Advisors LLC

May 16, 2025 | marketbeat.com

Dimensional Fund Advisors LP Purchases Shares of 64,384 MoonLake Immunotherapeutics (NASDAQ:MLTX)

May 16, 2025 | marketbeat.com

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

May 15, 2025 | zacks.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from Needham & Company LLC

May 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, CRNX, MLTX, and IMVT Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$20.04 -0.59 (-2.86%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$20.04 0.00 (0.00%)

As of 05/28/2025 04:13 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Crinetics Pharmaceuticals NASDAQ:CRNX

$29.91 +0.41 (+1.39%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$30.34 +0.43 (+1.42%)

As of 05/28/2025 07:57 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Immunovant NASDAQ:IMVT

$14.10 -0.19 (-1.33%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$14.41 +0.31 (+2.20%)

As of 05/28/2025 07:55 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

MoonLake Immunotherapeutics NASDAQ:MLTX

$38.17 -0.41 (-1.06%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$38.18 +0.02 (+0.04%)

As of 05/28/2025 07:59 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time